Insider Selling: Takeda Pharmaceutical (NYSE:TAK) CEO Sells $1,523,439.00 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) CEO Julie So-Young Kim sold 89,090 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $1,523,439.00. Following the transaction, the chief executive officer directly owned 391,489 shares in the company, valued at approximately $6,694,461.90. This represents a 18.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Up 1.5%

Shares of TAK opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The company’s fifty day moving average is $16.57 and its two-hundred day moving average is $17.14. The firm has a market cap of $56.53 billion, a PE ratio of 51.89 and a beta of -0.08. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. Analysts forecast that Takeda Pharmaceutical Co. will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold”.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC acquired a new position in shares of Takeda Pharmaceutical during the second quarter worth about $163,000. GAMMA Investing LLC grew its stake in shares of Takeda Pharmaceutical by 10.7% in the second quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after buying an additional 1,338 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Takeda Pharmaceutical by 10.8% in the second quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock valued at $684,000 after buying an additional 4,169 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 10.5% during the 1st quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after buying an additional 2,343 shares during the period. Finally, Glenmede Trust Co. NA raised its holdings in shares of Takeda Pharmaceutical by 9.6% during the 1st quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock valued at $559,000 after buying an additional 2,640 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.